Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Mao II who wrote (1479)	2/10/1999 9:40:00 PM
From: Rocketman	Read Replies (2) \| Respond to of 2135

Seems like a battle of words going on between BMY and ENMD and also between what is in this press article and what Holaday said on CNBC today. Company says hopeful cancer drug too hard to make Wednesday February 10, 8:11 pm Eastern Time biz.yahoo.com I don't think Folkman is so much the hypester as the company is. However, Folkman has a long history of what seem like promising molecules that never come to fruition and which get replaced with new promising molecules that never come to fruition. The super hypesters in this case were the NY Times article authors that got this mess going in the first place. What is really unfortunate is the black pall that companies and stocks like this cast over all of biotech. They just make the entire industry appear suspect. I expect ENMD to begin a long slow decline. $167M market cap and only about $35M cash. For them to do this themselves now, they are going to end up spending more than they would have if BMY was going to do it. Uhhh, to those who predicted that this would be a product in 1999, NOT! Rman